Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 57

Sort by

Sort Order Select

Journal Articles

Re-Induction and Targeted Conditioning with Anti-CD45 Iodine ( 131 I) Apamistamab [Iomab-B] Leads to High Rates of Transplantation and Successful Engraftment in Older Patients with Active, Relapsed or Refractory (rel/ref) AML after Failure of Chemotherapy and Targeted Agents: Preliminary Midpoint Results from the Prospective, Randomized Phase 3 Sierra Trial

Blood (2019) 134 (Supplement_1): 5642.

https://doi.org/10.1182/blood-2019-122776

Published: 2019

Journal Articles

Feasibility of Administering Anti-CD45 Iodine ( 131 I) Apamistamab [Iomab-B] for Re-Induction and Targeted Conditioning in Older Patients with Active, Relapsed or Refractory AML without Lead-Lined Rooms: Sierra Trial Experience at MSKCC

Bae P Chu, MPH, Neeta Pandit-Taskar, MD, Boglarka Gyurkocza, MD, Qing Liang, PhD, Daniel Miodownik, MPH, Vijay Reddy, MD PhD, Mark S. Berger, MD, Lawrence T. Dauer, PhD

Blood (2019) 134 (Supplement_1): 5839.

https://doi.org/10.1182/blood-2019-131230

Published: 2019

Journal Articles

Preliminary Phase 1 Data on the Safety and Efficacy of a Novel PET Radiotracer, 124 I-p5+14, for Imaging Systemic Amyloidosis

Blood (2019) 134 (Supplement_1): 3034.

https://doi.org/10.1182/blood-2019-128850

Published: 2019

Journal Articles

Sierra Clinical Trial Dosimetry Results Support Low Dose Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] for Targeted Lymphodepletion Prior to Adoptive Cell Therapy

Rajneesh Nath, MD, Eileen M Geoghegan, Matthew L. Ulrickson, MD, Jennifer A Spross, MA, Renee H Lichtenstein, BA, Sandy Konerth, MS, Darrell R. Fisher, PhD, Qing Liang, PhD, Dale Ludwig, PhD BS, Vijay Reddy, MD PhD, Mark S. Berger, MD, Boglarka Gyurkocza, MD

Blood (2019) 134 (Supplement_1): 1958.

https://doi.org/10.1182/blood-2019-128838

Published: 2019

Journal Articles

PP2A Activators Enhance Efficacy of FLT3 Inhibitors in FLT3-ITD Acute Myeloid Leukemia Cells through AKT Inactivation-Dependent Pim-1 and c-Myc Proteasomal Degradation

Mario Scarpa, PhD, Prerna Singh, MS, Shivani Kapoor, MS, Jonelle K. Lee, MS, Sandrine Niyongere, MD, Goutham Narla, MD PhD, Danilo Perrotti, MD PhD, Maria R. Baer, MD

Blood (2019) 134 (Supplement_1): 1276.

https://doi.org/10.1182/blood-2019-129011

Published: 2019

Journal Articles

Targeting XIAP Via Degradation of MDM-2 By MX69 in Aggressive Lymphomas

Sumera Khan, MSc, MD, Kyle Runckel, BS, Cory Mavis, BSc, MSc, Matthew J. Barth, MD, Francisco J. Hernandez-Ilizaliturri, MD

Blood (2018) 132 (Supplement 1): 5379.

https://doi.org/10.1182/blood-2018-99-118480

Published: 2018

Journal Articles

Effects of Proteasome Inhibition in the Anti-Tumor Activity of Venetoclax in Mantle Cell Lymphoma Pre-Clinical Models

Shalin K. Kothari, MD, Cory Mavis, BSc, MSc, Juan Gu, MD PhD, Francisco J. Hernandez-Ilizaliturri, MD

Blood (2018) 132 (Supplement 1): 2942.

https://doi.org/10.1182/blood-2018-99-116510

Published: 2018

Journal Articles

The Role of Autophagy in Multiple Myeloma Progression

Ioanna Savvidou, MD, Tiffany T. Khong, BSc,PhD, Andrew Spencer, MD

Blood (2017) 130 (Supplement 1): 5355.

https://doi.org/10.1182/blood.V130.Suppl_1.5355.5355

Published: 2017

Journal Articles

Critical Evaluation of Who 2016 Criteria for the Diagnosis of Polycythemia Vera: Distinction from JAK2V617+ Essential Thrombocythemia

Richard T Silver, MD, Spencer Krichevsky, BS

Blood (2017) 130 (Supplement 1): 4181.

https://doi.org/10.1182/blood.V130.Suppl_1.4181.4181

Published: 2017

Journal Articles

Buparlisib/BKM120 PI3 Kinase Therapy in B Cell and T Cell Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL): Identification of Resistance Pathways and Biomarker Discovery

Afshin Beheshti, PhD, Michael E Coyle, MD, Ravi Dashnamoorthy, PhD, Andrew M Evens, DO, MSc, FACP

Blood (2016) 128 (22): 2920.

https://doi.org/10.1182/blood.V128.22.2920.2920

Published: 2016

Journal Articles

Continued Excellent Outcomes in Previously Untreated Follicular Lymphoma Patients after Treatment with CHOP Plus Rituximab or CHOP Plus (131) Iodine-Tositumomab - Long Term Follow-up of Phase III Randomized Study SWOG S0016

Mazyar Shadman, MD MPH, Hongli Li, PhD, Lisa Rimsza, MD, John P. Leonard, MD, Mark S Kaminski, MD, Rita M Braziel, MD, Catherine M. Spier, MD, Ajay K Gopal, MD, David G Maloney, MD PhD, Bruce Cheson, MD, Shaker Dakhil, MD FACP, Michael LeBlanc, PhD, Sonali M. Smith, MD, Richard I. Fisher, MD, Jonathan W. Friedberg, MD, Oliver Press, MD PhD

Blood (2016) 128 (22): 616.

https://doi.org/10.1182/blood.V128.22.616.616

Published: 2016

Journal Articles

The PI3 Kinase (PI3K) Inhibitor, Buparlisib/BKM120, in B-Cell, T-Cell and Hodgkin Lymphoma Cell Lines: Cell Death Studies and Examination of Genomic Pathway Analyses Via a Systems Biology Approach

Michael E Coyle, MD, Ravi Dashnamoorthy, PhD, Afshin Beheshti, PhD, Andrew M. Evens, DO, MSc

Blood (2015) 126 (23): 1555.

https://doi.org/10.1182/blood.V126.23.1555.1555

Published: 2015

Journal Articles

Mitochondrial Apoptotic Priming Is Associated with Clinical Response to the Bcl-2 Antagonist ABT-199 in Chronic Lymphocytic Leukemia

Matthew S. Davids, MD, Jing Deng, PhD, Jeremy Ryan, SM, Stacey M. Fernandes, Jennifer R. Brown, Anthony G. Letai, MD PhD

Blood (2014) 124 (21): 1940.

https://doi.org/10.1182/blood.V124.21.1940.1940

Published: 2014

Journal Articles

Altered Glucose Metabolism In Rituximab-Chemotherapy Resistant Cells Is a Potential Target For Future Therapeutic Development

Juan Gu, PhD, Vivek Yanamadala, Cory Mavis, BSc, MSc, Francisco Hernandez, MD, Myron S. Czuczman, MD

Blood (2013) 122 (21): 4413.

https://doi.org/10.1182/blood.V122.21.4413.4413

Published: 2013

Journal Articles

The Dual Role Of Platelets In Thrombus Formation

Hadil Owaynat, BS, Valeryi K Lishko, PhD, James J Faust, BS, Tatiana P. Ugarova, PhD

Blood (2013) 122 (21): 1098.

https://doi.org/10.1182/blood.V122.21.1098.1098

Published: 2013

Journal Articles

Sterilization Of Catheters Using Providone-Iodine Decreases The Incidence Of Catheter-Associated Bloodstream Infection

Minako Sugiyama, MD, Yukayo Terashita, MD, Junjiro Ohshima, MD, PhD, Tomonobu Sato, MD, phD, Yuko Cho, MD, PhD, Akihiro Iguchi, MD, PhD

Blood (2013) 122 (21): 2984.

https://doi.org/10.1182/blood.V122.21.2984.2984

Published: 2013

Journal Articles

FAS Mutations Are Associated with Therapeutic Resistance in Follicular Lymphoma

Nathalie Johnson, MD, PhD, Denis Gaucher, PhD, Hawley Rigsby, Ryan D Morin, PhD, Joseph M. Connors, MD, Marco Marra, PhD, Randy D. Gascoyne, MD

Blood (2012) 120 (21): 1549.

https://doi.org/10.1182/blood.V120.21.1549.1549

Published: 2012

Journal Articles

RASA3 Plays a Critical, Conserved Role in Erythroid Differentiation

Lionel Blanc, PhD, Steven L. Ciciotte, MS, Jeffrey Michael Lipton, MD, PhD, Johnson M. Liu, MD, Luanne L. Peters, PhD

Blood (2012) 120 (21): 3186.

https://doi.org/10.1182/blood.V120.21.3186.3186

Published: 2012

Journal Articles

Combination of Epigenetic Agents Synergistically Reverse the Malignant Phenotype in Models of T-Cell Lymphoma

Enrica Marchi, MD, Ph.D., Matko Kalac, MD, Ph.D., Danielle C Bongero, Christine M McIntosh, Laura K Fogli, Luigi Scotto, Ph.D., Maura Rossi, Ph.D., Pier Luigi Zinzani, MD, PhD, Stefano Pileri, MD, Pier Paolo Piccaluga, Sr., MD, PhD, Owen A. O'Connor, MD, PhD

Blood (2011) 118 (21): 2727.

https://doi.org/10.1182/blood.V118.21.2727.2727

Published: 2011

Journal Articles

A Phase III Randomized Intergroup Trial (SWOG S0016) of CHOP Chemotherapy Plus Rituximab Vs. CHOP Chemotherapy Plus Iodine-131-Tositumomab for the Treatment of Newly Diagnosed Follicular Non-Hodgkin's Lymphoma

Oliver W. Press, MD, PhD, Joseph M Unger, Ph.D., Lisa M. Rimsza, MD, Jonathan Friedberg, MD, Michael LeBlanc, Ph.D., Myron S. Czuczman, MD, Mark S. Kaminski, MD, Rita M. Braziel, MD, David G. Maloney, MD, PhD, Bruce D. Cheson, MD, Thomas P. Miller, MD, Richard I Fisher, MD

Blood (2011) 118 (21): 98.

https://doi.org/10.1182/blood.V118.21.98.98

Published: 2011

NARROW

Feasibility of Administering Anti-CD45 Iodine ( 131 I) Apamistamab [Iomab-B] for Re-Induction and Targeted Conditioning in Older Patients with Active, Relapsed or Refractory AML without Lead-Lined Rooms: Sierra Trial Experience at MSKCC

Preliminary Phase 1 Data on the Safety and Efficacy of a Novel PET Radiotracer, 124 I-p5+14, for Imaging Systemic Amyloidosis

Sierra Clinical Trial Dosimetry Results Support Low Dose Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] for Targeted Lymphodepletion Prior to Adoptive Cell Therapy

PP2A Activators Enhance Efficacy of FLT3 Inhibitors in FLT3-ITD Acute Myeloid Leukemia Cells through AKT Inactivation-Dependent Pim-1 and c-Myc Proteasomal Degradation

Targeting XIAP Via Degradation of MDM-2 By MX69 in Aggressive Lymphomas

Effects of Proteasome Inhibition in the Anti-Tumor Activity of Venetoclax in Mantle Cell Lymphoma Pre-Clinical Models

The Role of Autophagy in Multiple Myeloma Progression

Critical Evaluation of Who 2016 Criteria for the Diagnosis of Polycythemia Vera: Distinction from JAK2V617+ Essential Thrombocythemia

Buparlisib/BKM120 PI3 Kinase Therapy in B Cell and T Cell Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL): Identification of Resistance Pathways and Biomarker Discovery

Continued Excellent Outcomes in Previously Untreated Follicular Lymphoma Patients after Treatment with CHOP Plus Rituximab or CHOP Plus (131) Iodine-Tositumomab - Long Term Follow-up of Phase III Randomized Study SWOG S0016

The PI3 Kinase (PI3K) Inhibitor, Buparlisib/BKM120, in B-Cell, T-Cell and Hodgkin Lymphoma Cell Lines: Cell Death Studies and Examination of Genomic Pathway Analyses Via a Systems Biology Approach

Mitochondrial Apoptotic Priming Is Associated with Clinical Response to the Bcl-2 Antagonist ABT-199 in Chronic Lymphocytic Leukemia

Altered Glucose Metabolism In Rituximab-Chemotherapy Resistant Cells Is a Potential Target For Future Therapeutic Development

The Dual Role Of Platelets In Thrombus Formation

Sterilization Of Catheters Using Providone-Iodine Decreases The Incidence Of Catheter-Associated Bloodstream Infection

FAS Mutations Are Associated with Therapeutic Resistance in Follicular Lymphoma

RASA3 Plays a Critical, Conserved Role in Erythroid Differentiation

Combination of Epigenetic Agents Synergistically Reverse the Malignant Phenotype in Models of T-Cell Lymphoma

A Phase III Randomized Intergroup Trial (SWOG S0016) of CHOP Chemotherapy Plus Rituximab Vs. CHOP Chemotherapy Plus Iodine-131-Tositumomab for the Treatment of Newly Diagnosed Follicular Non-Hodgkin's Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only